News for EDSA Stock

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference NEUPATH APPOINTS STEPHEN LEMIEUX AS PRESIDENT TO DRIVE NEXT PHASE OF STRATEGIC GROWTH Edesa Biotech Announces Chief Financial Officer Transition Edesa Biotech Reports Fiscal 1st Quarter 2025 Results Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Edesa Biotech Reports Fiscal Year 2024 Results Edesa Biotech’s Founder Makes Strategic Investment in the Company BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference Edesa Biotech to Participate in Upcoming Investor Conferences Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference Edesa Biotech to Participate in Barclays Global Healthcare Conference Edesa Biotech to Participate in Upcoming Dermatology Meetings Edesa Biotech Reports Fiscal 1st Quarter 2024 Results Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week Edesa Biotech Reports Fiscal Year 2023 Results Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study Edesa Biotech to Present at Dermatology Drug Development Summit Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug Edesa Biotech Secures $10 Million Credit Facility with Company Founder Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government Edesa Biotech Announces One-for-Seven Reverse Share Split Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate Edesa Biotech Reports Fiscal Third Quarter 2023 Results Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens Edesa Biotech Appoints Biotech Deal Veteran to CFO Role Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results Edesa Biotech to Participate in Swiss Biotech Day The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study Edesa Biotech Reports Fiscal 1st Quarter 2023 Results Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate Edesa Biotech Reports Fiscal Year 2022 Results Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference Edesa Biotech to Present at ARDS Drug Development Summit Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study Edesa Biotech to Present at H.C. Wainwright Global Investment Conference Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected Edesa Biotech Appoints Strategy Expert to Board of Directors Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study Edesa Biotech Reports Fiscal 1st Quarter 2022 Results Edesa Biotech to Join Ontario Bioscience Panel Discussion Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy Edesa Biotech Reports Fiscal Year 2021 Results Edesa Biotech Marks Enrollment Milestone in Dermatitis Study Edesa Biotech Extends COVID-19 Clinical Study to Poland Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results Edesa Biotech Extends Dermatitis Study to Canada Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment Edesa Biotech Reports Favorable Review of COVID-19 Study Edesa Biotech to Attend BIO Digital 2021 Edesa Biotech Reports Positive Interim Results in Dermatitis Trial Edesa Biotech to Join Panel Discussion at Industry Event Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results Edesa Biotech Expands Rights to Anti-Inflammatory Technology Edesa Biotech Reaches Enrollment Milestone in COVID Study Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares Edesa Biotech Reports Fiscal First Quarter 2021 Results Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy Edesa Biotech to Join Panel Discussion at Government COVID-19 Event Edesa Biotech Expands COVID-19 Clinical Study to Colombia Edesa Biotech Issues Letter to Shareholders Edesa Biotech Reports Fiscal Year 2020 Results Edesa Biotech Enrolls First Patient in COVID-19 Study Edesa Biotech to Present at H.C. Wainwright & Co. 6th Annual Israel Conference Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S. Pardeep Nijhawan Acquires Beneficial Ownership of Additional Securities of Edesa Biotech, Inc. Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results